Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Equinor ASA (EQNR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Equinor ASA — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Equinor ASA trades at $34.28 (market cap $78.18B). The key difference: Equinor ASA is the larger of the two by market cap, and Equinor ASA pays a 4.48% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | EQNR | |
|---|---|---|
Market Cap | $39.89B | $78.18B |
Sector | Health | Energy |
52-Week High | $491.22 | $42.40 |
52-Week Low | $278.09 | $22.41 |
Enterprise Value | $38.15B | $89.94B |
Dividend Yield | — | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Equinor (EQNR) trades at $33.92, down 0.26% today, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating estimates in Q4 2025 and Q1 2026 but missing in Q3 2025. Recent news highlights strategic investments in Norwegian Continental Shelf projects and a share buy-back program. Valuation ratios appear attractive with a P/E of 15.35 and EV/EBITDA of 2.27, though net income margin has declined to 5.3% in 2025 from 19.29% in 2022.
EQNR presents a value opportunity with low valuation multiples and ongoing shareholder returns via dividends and buybacks. However, declining profitability and negative net cash flow trends pose risks. Analyst sentiment is mixed with 30% buy ratings but 57% hold, suggesting cautious optimism. Key catalysts include production growth from recent investments, while oil price volatility and execution risks remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
